OxTalks will soon be transitioning to Oxford Events (full details are available on the Staff Gateway). A two-week publishing freeze is expected in early Hilary to allow all events to be migrated to the new platform. During this period, you will not be able to submit or edit events on OxTalks. The exact freeze dates will be confirmed as soon as possible.
If you have any questions, please contact halo@digital.ox.ac.uk
Claire is currently a Partner in the Life Science team at Oxford Science Enterprises, an investment company that creates transformational businesses via a unique partnership with the University of Oxford, UK, the world’s #1 research university. Her focus is building and investing in novel therapeutics and therapeutic platforms across diverse therapy areas and modalities. She currently supports a number of OSE’s emerging companies incl. T-Cypher Bio, Nucleome, Alveogene and Orfonyx. Claire has spent the majority of her career in the global BioPharmaceutical industry at UCB Group, Sanofi-Genzyme and AstraZeneca where she worked in a variety of roles covering R&D strategy, licensing and corporate VC.
